Risk-stratified analysis of pasireotide for patients undergoing pancreatectomy.

ABSTRACT:

Background and objectives

Pasireotide was shown in a randomized trial to decrease the rate of postoperative pancreatic fistula (POPF). However, retrospective series from other centers have failed to confirm these results.

Methods

Patients who underwent pancreatoduodenectomy or distal pancreatectomy between January 2014 and February 2019 were included. Patients treated after November 2016 routinely received pasireotide and were compared to a retrospective cohort. Multivariate analysis was performed for the outcome of clinically relevant POPF (CR-POPF), with stratification by fistula risk score (FRS).

Results

Ninety-nine of 300 patients received pasireotide. The distribution of high, intermediate, low, and negligible risk patients by FRS was comparable (P = .487). There

SUBMITTER: Peng JS 

PROVIDER: S-EPMC7369221 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature